WO2002077639A3 - Osteocalcin fragments assay to monitor bone resorption - Google Patents

Osteocalcin fragments assay to monitor bone resorption Download PDF

Info

Publication number
WO2002077639A3
WO2002077639A3 PCT/EP2002/003022 EP0203022W WO02077639A3 WO 2002077639 A3 WO2002077639 A3 WO 2002077639A3 EP 0203022 W EP0203022 W EP 0203022W WO 02077639 A3 WO02077639 A3 WO 02077639A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteocalcin
assay
fragments
bone resorption
monitor bone
Prior art date
Application number
PCT/EP2002/003022
Other languages
French (fr)
Other versions
WO2002077639A2 (en
Inventor
Paul Andreas Compare Cloos
Original Assignee
Osteometer Biotech As
Paul Andreas Compare Cloos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteometer Biotech As, Paul Andreas Compare Cloos filed Critical Osteometer Biotech As
Priority to AU2002257678A priority Critical patent/AU2002257678A1/en
Publication of WO2002077639A2 publication Critical patent/WO2002077639A2/en
Publication of WO2002077639A3 publication Critical patent/WO2002077639A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The amount of osteocalcin-derived fragments in a body fluid is measured by determining binding to said fragments of an immunological binding partner specific for a epitope located at the N or C terminus of a said fragment created upon cleavage of osteocalcin at said terminus during resorption of bone and which is not present in intact osteocalcin. The epitope may be created by cleavage by cathepsin K and may include an isomerised or optically inverted amino acid.
PCT/EP2002/003022 2001-03-23 2002-03-19 Osteocalcin fragments assay to monitor bone resorption WO2002077639A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257678A AU2002257678A1 (en) 2001-03-23 2002-03-19 Osteocalcin fragments assay to monitor bone resorption

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0107393A GB0107393D0 (en) 2001-03-23 2001-03-23 A method of assaying osteocalcin fragments in body fluids a test kit and means for carrying out the method and use of the method to monitor bone resorption
GB0107393.1 2001-03-23

Publications (2)

Publication Number Publication Date
WO2002077639A2 WO2002077639A2 (en) 2002-10-03
WO2002077639A3 true WO2002077639A3 (en) 2003-09-04

Family

ID=9911474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003022 WO2002077639A2 (en) 2001-03-23 2002-03-19 Osteocalcin fragments assay to monitor bone resorption

Country Status (3)

Country Link
AU (1) AU2002257678A1 (en)
GB (1) GB0107393D0 (en)
WO (1) WO2002077639A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302257D0 (en) 2013-02-08 2013-03-27 Nobel Biocare Services Ag Method for measuring bone loss rate
CN116626302B (en) * 2023-03-13 2023-11-10 宁波国际旅行卫生保健中心(宁波海关口岸门诊部) Biomarker for bone peptide intervention treatment of osteoporosis
CN118206647A (en) * 2024-03-14 2024-06-18 北京赛斯维德生物科技有限公司 Antibody and kit for detecting carboxylated osteocalcin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0410004A1 (en) * 1989-02-10 1991-01-30 Teijin Limited Immunoassay of human osteocalcin, reagent and kit therefor
EP0557663A1 (en) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Assessment of bone fragility and prediction of osteoporotic fracture risk using a quantitative determination of circulating under-carboxylated osteocalcin
WO1999009058A1 (en) * 1997-08-15 1999-02-25 Jukka Hellman Isolated osteocalcin fragments
US6107047A (en) * 1996-03-21 2000-08-22 Osteometer Biotech A/S Assaying protein fragments in body fluids
WO2000058732A1 (en) * 1999-03-29 2000-10-05 Kaekoenen Sanna Maria Method for prediction of bone fractures by osteocalcin measurements

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0410004A1 (en) * 1989-02-10 1991-01-30 Teijin Limited Immunoassay of human osteocalcin, reagent and kit therefor
EP0557663A1 (en) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Assessment of bone fragility and prediction of osteoporotic fracture risk using a quantitative determination of circulating under-carboxylated osteocalcin
US6107047A (en) * 1996-03-21 2000-08-22 Osteometer Biotech A/S Assaying protein fragments in body fluids
WO1999009058A1 (en) * 1997-08-15 1999-02-25 Jukka Hellman Isolated osteocalcin fragments
WO2000058732A1 (en) * 1999-03-29 2000-10-05 Kaekoenen Sanna Maria Method for prediction of bone fractures by osteocalcin measurements

Also Published As

Publication number Publication date
WO2002077639A2 (en) 2002-10-03
GB0107393D0 (en) 2001-05-16
AU2002257678A1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
DE60322188D1 (en) ZYTOKIN (ZCYTOR17-LIGAND)
WO2005003171A3 (en) Modified antibody fragments
ID28299A (en) RECEPTOR PROTEINS LIKE THE HUMAN TOLL OF RELATED METHODS AND REAGENTS
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
CA2336153A1 (en) Method for early diagnosis of carcinomas
WO2002008767A3 (en) Methods and kits for sequencing polypeptides
WO2004019043A3 (en) Polypeptide biomarkers for diagnosing alzheimer's disease
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
WO2003048207A3 (en) Anti-dota antibody
WO2001003719A3 (en) Combination therapy for conditions leading to bone loss
Arlaud et al. Complete amino acid sequence of the catalytic chain of human complement subcomponent C. hivin. 1r
EP1433792A8 (en) Human receptor proteins, related reagents and methods
ZA986974B (en) Method for diagnosis of metabolic bone diseases
EP1130401A3 (en) Assays for measurement of type II collagen fragments in urine
WO2002077639A3 (en) Osteocalcin fragments assay to monitor bone resorption
IL144129A0 (en) Methods and kits for sequencing polypeptides
WO2002059617A3 (en) Standard diluent for multiplex assays
WO2001014877A3 (en) Method of diagnosing sjogren's syndrome
WO2002033089A3 (en) Ixodes scapularis tissue factor pathway inhibitor
EP1245957A3 (en) Method of measuring ceruloplasmin concentration with enzyme-linked immunosorbent assay or dissociation-enhanced time-resolved fluoroimmunoassay in a blood spot, and Wilson's disease screening kit and method of diagnosing Wilson's disease
WO2005019471A3 (en) Periostin-like factor: compositions and methods for making and using the same
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use
WO1999050662A3 (en) Method of measuring bone resorption rate
WO2005051995A3 (en) Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
AU5736899A (en) A mutant of tissue factor pathway inhibitor, dna sequence and use for detecting thrombotic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP